#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Beth Burnside Email
SVP R&D Strategy . Maxwell Biosciences
How to contact Beth Burnside
Join and see Beth's contact info for free!Current Roles
Employees:
22Revenue:
$3.4MAbout
A New Virucide Drug By Mimicking Natural Human Antiviral Proteins Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented small molecule drugs that destroy SARS-CoV-2, the COVID virus, and other viruses. This world-first drug class called Maxwell's PeptoidsTM mimics natural human immune system antimicrobial peptides. Maxwell Biosciences recently announced confirmation by US Govt-funded labs that Maxwell's lead drug candidate has direct virucidal action against Herpes virus and SARS-CoV-2, the COVID-19 virus. Additionally, recent live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target†virucidal drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics. Maxwell is raising funds for advanced preclinical and human trials.Maxwell Biosciences Address
3809 Juniper TraceAustin, TX
United States